Halozyme Therapeutics Inc to Acquire Antares Pharma Inc to Create a Specialty Product and Drug Delivery Leader Call Transcript
Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme Conference Call and Webcast. (Operator Instructions)
Dawn Schottlandt, you may begin your conference.
Thank you, and good morning, everyone. Thank you for joining our call today to discuss Halozyme's acquisition of Antares Pharma. Joining me today is Dr. Helen Torley, Halozyme's President and Chief Executive Officer; Nicole LaBrosse, Halozyme's Chief Financial Officer, is also joining for the question-and-answer session.
As a reminder, this call is being recorded, and the press release and slide presentation regarding today's news are available on the Investor Relations section of Halozyme and Antares respective websites. This communication is not intended to constitute an offer to buy or sell or the solicitation of an offer to buy any securities or solicitation of any vote or approval. Antares intends to file (inaudible) with the SEC regarding the proposed
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |